title: Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma.
abstract: BACKGROUND
  Patients receiving cancer treatment are at risk for hepatitis B virus (HBV) reactivation. Ifosfamide is an alkylating agent and is considered to be one of the important drugs for the treatment of metastatic sarcoma. No association of ifosfamide and HBV reactivation has been reported so far.
  
  
  METHODS
  We report a case of a 61-year-old Asian man with metastatic retroperitoneal liposarcoma who was HBcAb positive and was treated with ifosfamide and dacarbazine, developed HBV reactivation secondary to ifosfamide requiring treatment with tenofovir. To the best of our knowledge, this is the first report describing HBV reactivation in a patient with positive HBcAb who was treated with ifosfamide.
  
  
  CONCLUSIONS
  We recommend close surveillance of possible HBV reactivation while employing ifosfamide chemotherapy.
authors.affiliation: Division of Hematology/Oncology, Brookdale University Hospital Medical center, Brooklyn, NY, USA.
authors.forename: Purva
authors.initials: P
authors.lastname: Chhibar
authors.affiliation: Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
authors.forename: Ziqiang
authors.initials: Z
authors.lastname: Zhu
authors.affiliation: Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
authors.forename: Naga K S
authors.initials: NK
authors.lastname: Cheedella
authors.affiliation: Department of Surgery, Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
authors.forename: Rashid
authors.initials: R
authors.lastname: Chaudhry
authors.affiliation: Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
authors.forename: Jen Chin
authors.initials: JC
authors.lastname: Wang
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D008080:Liposarcoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy*; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide